Clinical trial
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
NCT00651456 · Intergroupe Francophone de Cancerologie Thoracique, Other · Completed
Key facts
| NCT number | NCT00651456 |
|---|---|
| Title | Mesothelioma Avastin Plus Pemetrexed-cisplatin Study |
| Official title | A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) |
| Acronym | MAPS |
| Lead sponsor | Intergroupe Francophone de Cancerologie Thoracique, Other |
| Collaborators | University Hospital, Caen Groupe Francais De Pneumo-Cancerologie |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Mesothelioma |
| Intervention type | Drug |
| Interventions | Standard Chemotherapy (Pemetrexed and Cisplatin), Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab |
| Enrollment | 448 |
| Start date | Feb 1, 2008 |
| Primary completion | Jan 1, 2015 |
| Completion | Sep 1, 2016 |
| First posted | Apr 2, 2008 |
| Last update posted | Mar 13, 2023 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: